好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Impact of Race and Ethnicity on Time to Diagnosis of Multiple Sclerosis: Preliminary Results
Health Care Disparities
P17 - Poster Session 17 (11:45 AM-12:45 PM)
11-006

To assess for differences in the time from symptom onset to diagnosis of multiple sclerosis (MS) patients from various racial and ethnic groups

Clinical research can uncover and increase understanding around patterns of health care disparities. Diverse racial and ethnic representation in clinical research is also important to ensuring health equity. The NIH MS Natural History Protocol is a longitudinal observational study that evaluates patients with neuroinflammatory disorders while they remain under the care of an external primary neurologist. We sought to characterize the racial and ethnic composition of the cohort of patients enrolled in this study.

Cohort analysis of all patients in the NIH Multiple Sclerosis Natural History Protocol with confirmed diagnosis of MS. In this initial pilot analysis, the primary outcome measure was time from symptom onset to diagnosis based on history obtained from initial intake evaluation. Further analyses will restrict patients diagnosed with MS from 2010 onwards to control for changes to diagnostic criteria and evaluation.

Total cohort of 1279 patients, with preliminary data selected randomly from 20 patients with enrollment after 2005. Racial/ethnic breakdown: 8 non-Hispanic Black, 6 non-Hispanic White, 3 Hispanic, 2 non-Hispanic Asian, 1 multi-racial. Average time from symptom onset to diagnosis was 69.8 months in Black (SD 84.3, range 3-168), 18.2 months in White (SD 25.2, range 1-60), 19.7 months in Hispanic (SD 4.0, range 16-24), 21.5 months in Asian (SD 20.5, range 7-36), 1 month in multi-racial. Lack of insurance was noted in the clinician’s report to cause delay in diagnosis in 1 Asian and 1 Black patient. 

There is a growing body of literature that shows that underrepresented racial/ethnic minorities with MS experience a worse disease course. The reasons for this unequal burden of disease are not well understood, but inequities in diagnostic delay may play a role.

Authors/Disclosures
Jemima Akinsanya, DO (NIH)
PRESENTER
Dr. Akinsanya has nothing to disclose.
Frances Andrada No disclosure on file
Karan D. Kawatra, Other Mr. Kawatra has nothing to disclose.
No disclosure on file
Joan M. Ohayon (National Institutes of Health) Joan M. Ohayon has nothing to disclose.
Daniel Reich, MD, PhD (National Institutes of Health, Neuroimmunology Branch, NINDS) Dr. Reich has received research support from NIH. The institution of Dr. Reich has received research support from Adelson Medical Research Foundation. The institution of Dr. Reich has received research support from Sanofi. The institution of Dr. Reich has received research support from Abata Therapeutics. The institution of Dr. Reich has received research support from National Multiple Sclerosis Society. The institution of Dr. Reich has received research support from Cure Alzheimer's Fund. Dr. Reich has received intellectual property interests from a discovery or technology relating to health care. Dr. Reich has received personal compensation in the range of $5,000-$9,999 for serving as a CME Faculty with Integrity. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Letters and Sciences. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Academic CME. Dr. Reich has a non-compensated relationship as a Advisor with Sanofi that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Board of Directors with ACTRIMS that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Abata Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with University of Basel RC2NB that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Multiple Sclerosis Society of Canada that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Tuscan Doctorate in Neuroscience that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Editorial Board with Multiple Sclerosis Journal that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Hyperfine that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Imaginab that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Annexon that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Philips that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Siemens that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Calico Life Sciences that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Cognito Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Sudo that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Allumis that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with BioCentury that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Regeneron that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Eli Lilly that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with SetPoint that is relevant to AAN interests or activities.
Irene Cortese, MD Dr. Cortese has stock in Keires, AG. Dr. Cortese has stock in Nouscom, AG. Dr. Cortese has stock in PDC*line Pharma.
Shila Azodi, MD (FOOD AND DRUG ADMINISTRATION) Dr. Azodi has nothing to disclose.